On November 4, TD Cowen maintained its Buy rating and $1,230 price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), reflecting strong third-quarter results and a discussion with CEO Len ...

Regeneron’s motto comes from my partner Len Schleifer’s father: Do well by doing good. We don’t go after diseases by how much money can be made. Regeneron considers whether we can make an ...

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $917.00. The company’s shares closed ...

“There are long lists of diseases hypothesized to be driven by IL-1,” CEO Len Schleifer noted. “We are looking to test them relatively systematically over the years to come.” The Regeneron ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Future of Healthcategory· February 24, 2025 Regeneron's gene therapy study shows improved hearing in children with congenital deafness Regeneron Pharmaceuticals said on Monday its experimental ...

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle ...

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in the ...

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...

“There are long lists of diseases hypothesized to be driven by IL-1,” CEO Len Schleifer noted. “We are looking to test them relatively systematically over the years to come.” The Regeneron ...